Skip to main content

Table 4 Cardiac function

From: Efficacy and safety of intracoronary prourokinase during percutaneous coronary intervention in treating ST-segment elevation myocardial infarction patients: a randomized, controlled study

 

Intracoronary prourokinase group (N = 25)

Control group (N = 25)

P value

1-day LVEF, mean ± SD, %

55.81 ± 5.86

55.60 ± 5.69

0.899

1-day LVEDd, mean ± SD, cm

4.80 ± 0.29

4.81 ± 0.32

0.938

1-day WMSI, mean ± SD

2.12 ± 0.23

2.14 ± 0.24

0.724

3-month LVEF, mean ± SD, %

60.84 ± 2.29

59.18 ± 2.44

0.017

3-month LVEDd, mean ± SD, cm

4.73 ± 0.19

4.89 ± 0.25

0.013

3-month WMSI, mean ± SD

1.84 ± 0.16

1.95 ± 0.15

0.015

  1. Differences between two groups were determined by Student’s t-test. LVEF left ventricular ejection fraction, LVEDd left ventricular end-diastolic diameters, WMSI wall motion score index
Back to article page